GFP
NTLA icon

Gryphon Financial Partners’s Intellia Therapeutics NTLA Stock Holding History

Gryphon Financial Partners’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-24
Closed -$1K – 615
2018
Q2 		$1K Sell
24
-125
-84% -$3.03K ﹤0.01% 926
2018
Q1 		$3K Buy
149
+49
+49% +$1.21K ﹤0.01% 798
2017
Q4 		$2K Buy
+100
New +$2.31K ﹤0.01% 922

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Chevy Chase Trust
Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return

Gryphon Financial Partners's NTLA Position: Q3 2018 in Review

Gryphon Financial Partners sold out of Intellia Therapeutics (NTLA) in Q3 2018, closing a stake of 24 shares — an estimated $1K sold.

Gryphon Financial Partners first reported a position in NTLA in Q4 2017 and held it in 3 quarters. The position peaked at $3K in Q1 2018. 157 funds tracked by Wall St. Rank hold NTLA as of Q3 2018.

  • Gryphon Financial Partners reported no remaining Intellia Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Gryphon Financial Partners sold 24 Intellia Therapeutics shares in Q3 2018, an estimated $1K.
  • Gryphon Financial Partners first reported a position in Intellia Therapeutics in Q4 2017 and held it in 3 quarters.
  • Gryphon Financial Partners's Intellia Therapeutics position peaked at $3K in Q1 2018.
  • 157 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2018.

Based on Gryphon Financial Partners's 13F filing for Q3 2018, filed 6 Nov 2018.